Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level <=2%) haemophilia B.
Windyga, J. 1; Lissitchkov, T. 2; Stasyshyn, O. 3; Mamonov, V. 4; Rusen, L. 5; Lamas, J. L. 6; Oh, M.-S. 7; Chapman, M. 8; Fritsch, S. 8; Pavlova, B. G. 8; Wong, W.-Y. 7; Abbuehl, B. E. 8
[Article] Haemophilia. 20(1):15-24, January 2014.

(Format: HTML, PDF)